Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 1/20 | 0.50 |
| ▸ | GABRD | O14764 | 1/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.50 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.50 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.50 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.50 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.50 |
| ▸ | GABRE | P78334 | 1/20 | 0.50 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.50 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.50 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.50 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4154226 | 0.88 | NFKB1 (0.54) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL4604609 | 0.86 | NPC1 (0.40) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL10723761 | 0.86 | RAB9A (0.54) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2823763 | 0.84 | RAB9A (0.57) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL30279718 | 0.82 | — | — | |
| SCHEMBL312816 | 0.82 | — | — | |
| SCHEMBL25054208 | 0.80 | GABRP (0.52) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL19001246 | 0.80 | NOS1 (0.41) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1626973 | 0.78 | GABRP (0.55) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Hydrochloric Acid SCHEMBL23201156 | 0.78 | GABRP (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3960735-B1 | QUINAZOLINE DERIVATIVES USED TO TREAT HIV | GILEAD SCIENCES INC (US) | 2023-09-13 | — | — | EP | disclosed |
| WO-2023086465-A1 | COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | MODERNATX, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2022152852-A1 | ANTAGONISTS OF MRGX2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-07-21 | — | — | WO | disclosed |
| WO-2021035101-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | BIOHAVEN THERAPEUTICS LTD. (US) | 2021-02-25 | — | — | WO | disclosed |
| US-20140031334-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| US-8598162-B2 | Derivatives of 4-piperazin-1-yl-4-benzo[B]thiophene suitable for the treatment of CNS disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-12-03 | — | — | US | disclosed |
| US-20130005674-A1 | ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS | ISIS PHARMACEUTICALS, INC. (US) | 2013-01-03 | — | — | US | disclosed |
| CN-102850336-A | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMA CO LTD | 2013-01-02 | — | — | CN | disclosed |
| CN-102702182-A | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | OTSUKA PHARMA CO LTD | 2012-10-03 | — | — | CN | disclosed |
| CN-102558140-A | Derivatives of 4-piperazin-1-1-yl-4-benzo [b] thiophene suitable for the treatment of cns disorders | OTSUKA PHARMA CO LTD | 2012-07-11 | — | — | CN | disclosed |
| EP-1943234-A1 | TRIAZOLE COMPOUNDS AS LIPOXYGENASE INHIBITORS | Biolipox AB (SE) | 2008-07-16 | — | — | EP | disclosed |
| EP-1919907-A2 | HETEROCYCLIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-05-14 | — | — | EP | disclosed |
| US-20080045468-A1 | ANTIMICROBIAL 2-DEOXYSTREPTAMINE COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | US | disclosed |
| WO-2008014221-A2 | BRIDGED CARBAMATE MACROLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| WO-2007051981-A1 | PYRAZOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007051982-A1 | TRIAZOLE COMPOUNDS AS LIPOXYGENASE INHIBITORS | BIOLIPOX AB (SE) | 2007-05-10 | — | — | WO | disclosed |
| US-20070082853-A1 | 6, 11-bridged tricyclic macrolides | ENANTA PHARMACEUTICAL, INC. | 2007-04-12 | — | — | US | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
| WO-2005085252-A1 | IMIDAZO ‘1,2-A’ PYRAZINE COMPOUNDS WHICH INTERACT WITH PROTEIN KINASES | BIOFOCUS DISCOVERY LIMITED (GB) | 2005-09-15 | — | — | WO | disclosed |
| US-4457932-A | GASTROINTESTINAL DISORDERS | BRISTOL-MYERS COMPANY (US) | 1984-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005674-A1 | ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS | ALG8, MRPL21, AADAC | GABRP 3357/4885GABRD 2703/4885GABRA1 4006/4885 |
| US-20140031334-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | GRIN2C, GRIN2B, PMP22 | GABRP 294/4885GABRD 602/4885GABRA1 56/4885 |
| US-20080045468-A1 | ANTIMICROBIAL 2-DEOXYSTREPTAMINE COMPOUNDS | MTAP, UNG, PNMT | GABRP 4702/4885GABRD 4555/4885GABRA1 4845/4885 |
| US-20070082853-A1 | 6, 11-bridged tricyclic macrolides | CYP2B6, CYP2D6, ABCB11 | GABRP 4221/4885GABRD 3742/4885GABRA1 4246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.